Application effect of recombinant human epidermal growth factor derivative Eye drops in treatment of dry eye
10.3980/j.issn.1672-5123.2015.1.33
- VernacularTitle:重组人表皮生长因子衍生物滴眼剂在治疗干眼中的应用
- Author:
Yan-Chun, WANG
- Publication Type:Journal Article
- Keywords:
dry eye;
recombinant human epidermal growth factor derivative eye drops;
Chondroitin sulfate eye drops;
life quality evaluation standard SF-36
- From:
International Eye Science
2015;(1):117-119
- CountryChina
- Language:Chinese
-
Abstract:
Abstract? AlM: To investigate the application effect of recombinant human epidermal growth factor derivative eye drops ( Jinyinshu) in treatment of dry eye.?METHODS:Sixty cases ( 87 eyes ) of dry eye patients were randomly divided into control group and observation group, 42 eyes and 45 eyes respectively. The control group received Chondroitin sulfate eye drops treatment, and the observation group were used for treatment of Jinyinshu. The changes of clinical efficacy, correlation index (symptom score, BUT, S l t, FL) before and after treatment, quality of life after treatment and the incidence of adverse reactions were compared.? RESULTS: ln the control group, the total clinical effective rate was 71%, which was significantly lower than that in the observation group ( 91%) , the difference was statistically significant ( P<0. 05 ); There were statistical differences of symptom scores, BUT, S▏t and FL level of the two groups before and after treatment (P<0. 05), and there were statistical differences of the above indexes after treatment between the two groups ( P<0. 05 ); The quality of life score was 142. 16 ± 10. 32 of the observation group after treatment, which was significantly higher than that in the control group after treatment (115. 24±7. 34), the difference was statistically significant (P<0. 05); The incidence of adverse reaction of the control group was 13%, 10% in the observation group, and there were no statistical differences (P>0. 05).?CONCLUSlON:Jinyinshu is significantly effective in the treatment of dry eye, and its clinical efficacy is better than chondroitin sulfate.
